Stryker Corporation
SYK
$345.81
+2.00%
Stryker Corporation is a leading medical technology company that designs, manufactures, and markets a broad portfolio of medical devices, including orthopedic implants, surgical equipment, neurotechnology, and patient care products. As one of the three largest players in reconstructive orthopedic implants and the market leader in operating room equipment, Stryker holds a dominant competitive position in the healthcare sector. The current investor narrative centers on the company's strategic acquisitions, such as the recent purchase of Amplitude Vascular Systems to enhance its peripheral vascular offerings, alongside its robust financial performance and ongoing innovation in robotics and digital surgery. Despite a challenging market environment that has pressured the stock over the past year, Stryker's consistent revenue growth and strong free cash flow generation continue to attract investor attention.…
SYK
Stryker Corporation
$345.81
Related headlines
Investment Opinion: Should I buy SYK Today?
Based on the analysis, Stryker is rated a 'Buy' with a thesis that its dominant market position, consistent revenue growth, and strong cash flow generation justify its premium valuation. The consensus analyst rating is 'Buy' with an average target of $381.50, implying 13.1% upside. This is supported by the company's 2.6% revenue growth, 63.3% gross margin, and $4.57 billion in free cash flow, which provide a solid foundation for future growth.
Sign up to view all
SYK 12-Month Price Forecast
The AI assessment is bullish on Stryker, driven by its strong market position, consistent revenue growth, and robust cash flow. The valuation is high but justified by the company's quality and growth prospects. However, the medium confidence reflects the risks of margin compression and potential valuation de-rating. The stance would be upgraded to high confidence if revenue growth accelerates above 5% and margins expand, while a downgrade to neutral would occur if growth falls below 2% or margins deteriorate further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $382.04 and implied upside of +10.5% versus the current price.
Average Target
$382.04
0 analysts
Implied Upside
+10.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$315 - $465
Analyst target range
Stryker is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.61 (where 1 is Strong Buy and 5 is Sell). The average price target is $381.50, implying an upside of approximately 13.1% from the current price of $337.43. The distribution of ratings is bullish, with recent actions from firms like BMO Capital upgrading to Outperform and Evercore ISI reiterating Outperform, while Truist Securities maintains a Hold, indicating a generally positive but not unanimous sentiment. The target price range spans from a low of $315.00 to a high of $465.00, reflecting a wide spread of 47.6% from low to high, which signals considerable uncertainty about the company's future performance. The high target of $465 assumes strong execution on growth initiatives and multiple expansion, while the low target of $315 prices in potential margin compression or competitive pressures. The recent upgrades and consistent Buy ratings suggest analysts are confident in Stryker's long-term prospects, but the wide range highlights the risks associated with the healthcare sector and macroeconomic conditions.
Bulls vs Bears: SYK Investment Factors
Stryker presents a mixed picture: strong fundamentals with dominant market positions, consistent revenue, and robust cash flow, but offset by a high valuation and recent margin compression. The bull case rests on the company's ability to sustain growth and expand margins, while the bear case hinges on valuation risk and competitive pressures. Currently, the evidence slightly favors the bull side due to the company's proven resilience and analyst optimism, but the key tension is whether the premium valuation can be justified by future growth. If revenue growth accelerates and margins stabilize, the stock could re-rate higher; otherwise, it risks a correction toward the lower end of analyst targets.
Bullish
- Dominant Market Position: Stryker is one of the three largest players in reconstructive orthopedic implants and the market leader in operating room equipment. This leadership provides pricing power and a competitive moat that supports consistent revenue generation.
- Consistent Revenue Growth: Q1 2026 revenue grew 2.6% YoY to $6.02 billion, with quarterly revenues over the past year ranging from $5.87 billion to $7.17 billion. This stability indicates resilient demand across its MedSurg and Orthopaedics segments.
- Strong Free Cash Flow: Free cash flow (TTM) stands at $4.57 billion, providing ample liquidity for dividends, share buybacks, and strategic acquisitions. This financial flexibility supports long-term shareholder returns and growth initiatives.
- Healthy Profitability: Gross margin is 63.3% and operating margin is 15.5% (Q1 2026), reflecting efficient operations and a strong product mix. Despite margin compression from 20.1% a year ago, profitability remains robust.
Bearish
- Underperformance vs. Market: SYK fell 10.0% over the past year while the S&P 500 gained 21.5%, a relative underperformance of 31.5 percentage points. This suggests company-specific or sector headwinds that have weighed on the stock.
- High Valuation Premium: Trailing P/E is 41.4x and forward P/E is 20.1x, with a PEG ratio of 5.16, indicating the market expects aggressive growth. This premium leaves little room for error and could compress if growth disappoints.
- Margin Compression: Operating margin fell from 20.1% in Q1 2025 to 15.5% in Q1 2026, and net margin dropped from 14.2% to 12.4%. Rising operating expenses are pressuring profitability, which could continue if not managed.
- Modest Revenue Growth: Q1 2026 revenue growth of only 2.6% YoY is sluggish for a company with a PEG of 5.16. If this pace persists, it may not justify the premium valuation, leading to multiple compression.
SYK Technical Analysis
Stryker's stock is currently in a recovery phase after a significant downtrend, with the price at $337.43 as of August 6, 2026, reflecting a 10.0% decline over the past year. The stock is trading at approximately 85% of its 52-week range (low of $281.00 and high of $396.86), indicating it has recovered from the lows but remains below its peak. This positioning suggests a potential value opportunity if the recovery continues, but also highlights the risk of a falling knife if the broader downtrend resumes. The 1-year price change of -10.0% contrasts sharply with the S&P 500's +21.5% gain, underscoring significant underperformance relative to the market.
Beta
0.77
0.77x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$397
Price range past year
Annual Return
-8.4%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +4.9% | +2.4% |
| 3m | +17.4% | +4.7% |
| 6m | -4.9% | +11.7% |
| 1y | -8.4% | +21.3% |
| ytd | -0.7% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue trajectory remains solid, with the most recent quarter (Q1 2026) reporting revenue of $6.02 billion, a 2.6% year-over-year increase. This growth is modest but consistent, with quarterly revenues over the past year ranging from $5.87 billion to $7.17 billion, reflecting stable demand across its MedSurg and Orthopaedics segments, which generated $3.21 billion and $2.81 billion respectively in the latest quarter. The company's gross margin stands at 63.3%, while operating margin is 15.5%, indicating healthy profitability, though the operating margin has compressed from 20.1% in Q1 2025 due to increased operating expenses. Net income for Q1 2026 was $745 million, with a net margin of 12.4%, down from 14.2% in the prior year quarter, but still demonstrating robust earnings power.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$4.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given Stryker's positive net income, the trailing P/E ratio of 41.4x is the primary valuation metric, while the forward P/E of 20.1x suggests the market expects significant earnings growth, as reflected in the PEG ratio of 5.16. The stock trades at a premium to the sector, with a price-to-sales ratio of 5.35x and EV/EBITDA of 23.2x, compared to industry averages that are typically lower for medical device companies. This premium is justified by Stryker's strong brand, innovative product pipeline, and consistent cash flow generation, but it also leaves little room for error. Historically, the stock's P/E has ranged from 23.4x to 77.7x over the past five years, with the current level near the middle of that range, suggesting that the market is pricing in moderate growth expectations rather than extreme optimism or pessimism.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.73, which is manageable but elevated, and a payout ratio of 39.6%, indicating a commitment to dividends that could strain cash if earnings decline. The company's operating margin compression from 20.1% to 15.5% in a year suggests rising costs, and the high PEG ratio of 5.16 implies that any earnings miss could trigger a sharp de-rating. Additionally, free cash flow of $4.57 billion is strong, but it could be impacted by increased capital expenditures or acquisition integration costs.
FAQ
The key risks include: 1) Valuation risk - the high P/E and PEG ratios leave little room for error, and any growth disappointment could lead to multiple compression. 2) Margin risk - operating margin has declined from 20.1% to 15.5% in a year, and if this trend continues, profitability will suffer. 3) Competitive risk - Stryker faces intense competition from Boston Scientific and other medtech firms, which could erode market share. 4) Macro risk - healthcare policy changes, such as reimbursement cuts, could impact revenue. The most severe risk is a combination of these factors, which could drive the stock down to the 52-week low of $281.
The 12-month forecast for Stryker is moderately bullish. The base case, with a 50% probability, targets a range of $360-$400, aligning with the average analyst target of $381.50. The bull case, with a 30% probability, targets $400-$465, driven by strong execution and margin expansion. The bear case, with a 20% probability, targets $281-$315, if growth stalls or margins compress. The most likely scenario is the base case, assuming revenue growth remains around 2-3% and margins stabilize. Investors should monitor quarterly results for signs of acceleration or deterioration.
Stryker is trading at a premium to the sector, with a trailing P/E of 41.4x and a forward P/E of 20.1x, compared to industry averages that are typically lower. The PEG ratio of 5.16 suggests the market expects very high growth, which may be optimistic given the modest 2.6% revenue growth. Historically, the stock's P/E has ranged from 23.4x to 77.7x, so the current level is near the middle, indicating it is not extremely overvalued. The market is pricing in moderate growth expectations, and the stock appears fairly valued relative to its own history but slightly overvalued compared to peers.
Stryker is a good buy for investors seeking a high-quality medical device company with a dominant market position and consistent cash flow. The stock offers a 13.1% upside to the average analyst target of $381.50, and the consensus rating is 'Buy'. However, the high valuation (P/E 41.4x trailing) and recent margin compression pose risks. It is best suited for long-term investors who can tolerate short-term volatility and are willing to pay a premium for quality. A better entry point would be below $320, but the current price is still reasonable for a company with Stryker's fundamentals.
Stryker is more suitable for long-term investment due to its stable growth, strong cash flow, and dominant market position. The stock has a beta of 0.77, indicating lower volatility than the market, but it has experienced significant drawdowns (max -30%) in the past. The dividend yield of 0.96% provides a small income component, but the main return driver is capital appreciation. Given the high valuation and modest near-term growth, a holding period of at least 3-5 years is recommended to allow the company's growth initiatives to materialize. Short-term traders may find opportunities around earnings announcements, but the stock's volatility makes it less suitable for short-term speculation.